Drug Trial Radar · NCT00163137
Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss
Last checked: Nov 19, 2026Latest source record: Aug 12, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
540
Actual
Start
May 2003
Primary completion
Oct 2005
Study completion Oct 2005
Sponsor
- Lead sponsor
- Ligand PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Sep 13, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- Female only, from 48 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To compare the effects of 2 years of lasofoxifene treatment with 2 years of raloxifene 60 mg/day use and 2 years of placebo use on bone mineral density (BMD) of the lumbar spine.
Conditions
- Osteoporosis
Interventions
lasofoxifeneDrug
lasofoxifene 0.25mg
raloxifeneDrug
raloxifene 60 mg/day
PlaceboDrug
0 mg/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Spine BMD after 2 yearsTime frame: 2 years
Locations
72 sites in 1 country. Site status is shown where the registry gives one.
Pfizer Investigational Site
Albany, California
Pfizer Investigational Site
Berkeley, California
Pfizer Investigational Site
La Jolla, California
Pfizer Investigational Site
La Jolla, California
Pfizer Investigational Site
Oakland, California
Pfizer Investigational Site
Oakland, California
Pfizer Investigational Site
Palo Alto, California
Pfizer Investigational Site
Poway, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
Newark, Delaware
Pfizer Investigational Site
Brandon, Florida
Pfizer Investigational Site
Gainesville, Florida
Pfizer Investigational Site
Gainesville, Florida
Pfizer Investigational Site
Key Largo, Florida
Pfizer Investigational Site
Lake Worth, Florida
Pfizer Investigational Site
Leesburg, Florida
Pfizer Investigational Site
Miami, Florida
Pfizer Investigational Site
Miami, Florida
Pfizer Investigational Site
Miami, Florida
Pfizer Investigational Site
Tampa, Florida
Pfizer Investigational Site
Tampa, Florida
Pfizer Investigational Site
Tampa, Florida
Pfizer Investigational Site
West Palm Beach, Florida
Pfizer Investigational Site
Atlanta, Georgia
Pfizer Investigational Site
Chicago, Illinois
Pfizer Investigational Site
Des Moines, Iowa
Pfizer Investigational Site
Wichita, Kansas
Pfizer Investigational Site
Portland, Maine
Pfizer Investigational Site
Bethesda, Maryland
Pfizer Investigational Site
Gaithersberg, Maryland
Pfizer Investigational Site
Detroit, Michigan
Pfizer Investigational Site
Detroit, Michigan
Pfizer Investigational Site
Southfield, Michigan
Pfizer Investigational Site
Arden Hills, Minnesota
Pfizer Investigational Site
Minneapolis, Minnesota
Pfizer Investigational Site
Albuquerque, New Mexico
Pfizer Investigational Site
Albuquerque, New Mexico
Pfizer Investigational Site
Akron, Ohio
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.